Immunotherapy with Dendritic Cells as a Cancer Treatment: Perspectives and Therapeutic Potential

ISSN: 2212-3334 (Online)
ISSN: 1872-2148 (Print)


Volume 8, 3 Issues, 2014


Download PDF Flyer




Recent Patents on Endocrine Metabolic & Immune Drug Discovery

Aims & ScopeAbstracted/Indexed in


Submit Abstracts Online Submit Manuscripts Online

View Full Editorial Board

Subscribe Purchase Articles Order Reprints


Immunotherapy with Dendritic Cells as a Cancer Treatment: Perspectives and Therapeutic Potential

Author(s): Andre A.R. Aleixo, Márcia A. Michelin and Eddie F.C. Murta

Affiliation: Oncology Research Institute (IPON)/ Discipline of Gynecology and Obstetrics, (UFTM), Avenida Getulio Guarita, sn, Uberaba (MG), CEP 38025-440, Bairro Abadia, Brazil.

Abstract

The immune system, which is indispensible for controlling neoplasias, relies on its innate and acquired immunity components to mount an effective response against tumors. In this context, dendritic cells (DCs) are seen as the best antigen-presenting cells because of their capacity for cross-presentation, which can activate both T-helper and cytotoxic lymphocytes. Thus immunotherapy with DCs is considered promising, especially for early-stage cancers. This article provides a clarifying review of recent perspectives on the development of cancer immunotherapy, which has a wide potential for therapeutic applications, and of patents related to immunotherapy with DCs.

Keywords: Cancer, dendritic cells, immunotherapy, immune response, therapeutic potential, tumor.

Purchase Online Rights and Permissions

  
  



Article Details

Volume: 7
Issue Number: 3
First Page: 226
Last Page: 232
Page Count: 7
DOI: 10.2174/18722148113079990001
Advertisement

Related Journals




Webmaster Contact: urooj@benthamscience.org Copyright © 2014 Bentham Science